Clinical Trials Browser

Approved for marketing × amivantamab × 1 year × Clear all

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing

Carcinoma, Non-Small-Cell Lung